Abelacimab, formerly known as MAA868, represents a groundbreaking approach to treating thrombosis. This antiplatelet agent is a targeted monoclonal antibody that inhibits the integrin αIIbβ3, a critical player in https://kalektwz607251.blognody.com/49519521/abelacimab-maa868-a-deep-examination-into-the-new-blood-clot-treatment